Search
Search
About
Log in
Join
Experiences with
Abiraterone
Posts
Communities
1,352 public posts
Filter results
Need some help
I then restarted
Abiraterone
and had a good drop in PSA after 2 weeks but then i had three consecutive increases and
Abiraterone
has now been stopped with my PSA at 5 So my question is i have been offered treatment that i can not find much information on here in the UK and was after your thoughts, so
I then restarted
Abiraterone
and had a good drop in PSA after 2 weeks but then i had three consecutive increases and
Abiraterone
has now been stopped with my PSA at 5 So my question is i have been offered treatment that i can not find much information on here in the UK and was after your thoughts, so
siness
in
Advanced Prostate Cancer
6 years ago
I am new here, I am from Australia, I have extensive mets.
I will start
abiraterone
and pred. after the rays. Anyone else had LU PSMA in similar circumstances?
I will start
abiraterone
and pred. after the rays. Anyone else had LU PSMA in similar circumstances?
Metungboy
in
Advanced Prostate Cancer
6 years ago
Is AR-V7 Testing Pointless?
Neither
abiraterone
nor enzalutamide can have therapeutic activity against AR-V7 cells.
Neither
abiraterone
nor enzalutamide can have therapeutic activity against AR-V7 cells.
pjoshea13
in
Advanced Prostate Cancer
6 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Ralaniten [EPI-506]
anti-androgens mentions Ralaniten (aka EPI-506) as a: "novel first-in-class drug ... which binds to a unique region in the N-terminus domain of both the full-length and the truncated constitutively active splice variants of the AR, {&} is currently in clinical trials for patients who previously received
abiraterone
anti-androgens mentions Ralaniten (aka EPI-506) as a: "novel first-in-class drug ... which binds to a unique region in the N-terminus domain of both the full-length and the truncated constitutively active splice variants of the AR, {&} is currently in clinical trials for patients who previously received
abiraterone
pjoshea13
in
Advanced Prostate Cancer
6 years ago
What is mCRPC
The proper categorization matters because I am eligible for the
abiraterone
olaparib trial if I am castration resistant. Has anyone else been down this road? Any thoughts on how I should be categorized?
The proper categorization matters because I am eligible for the
abiraterone
olaparib trial if I am castration resistant. Has anyone else been down this road? Any thoughts on how I should be categorized?
ewhite999
in
Advanced Prostate Cancer
6 years ago
Abiraterone effectiveness time
My first treatment is for ADT and
Abiraterone
. I would like to know about experiences with Abiraterona. And times of effectiveness. A hug to everyone and a lot of luck
My first treatment is for ADT and
Abiraterone
. I would like to know about experiences with Abiraterona. And times of effectiveness. A hug to everyone and a lot of luck
joancarles
in
Advanced Prostate Cancer
7 years ago
Positive mind and advanced prostate cancer
The truth is, the treatment of ADT +
Abiraterone
is working well. I have no pain, I have taken weight and my PSA has dropped from 1350, at the time of diagnosis, to 0.2 in the last revision. My oncologist tells me that everything is going very well.
The truth is, the treatment of ADT +
Abiraterone
is working well. I have no pain, I have taken weight and my PSA has dropped from 1350, at the time of diagnosis, to 0.2 in the last revision. My oncologist tells me that everything is going very well.
joancarles
in
Advanced Prostate Cancer
7 years ago
Docetaxel for Prostate Cancer: 'Win-Win-Win'Nick Mulcahy
How Does This Compare to
Abiraterone
? The new data prompted Sumanta K.
How Does This Compare to
Abiraterone
? The new data prompted Sumanta K.
Hidden
in
Advanced Prostate Cancer
7 years ago
Recent article about Lutetium 177 treatment in advanced mCRPC by doctors at the Technical University of Munich
Eligibility criteria for 177Lu-PSMA-I&T therapy included previous treatment with
abiraterone
or enzalutamide, previous taxane-based chemotherapy or unsuitability for taxanes as well as positive 68Ga-PSMA tracer uptake of metastases in a prior PET-scan.
Eligibility criteria for 177Lu-PSMA-I&T therapy included previous treatment with
abiraterone
or enzalutamide, previous taxane-based chemotherapy or unsuitability for taxanes as well as positive 68Ga-PSMA tracer uptake of metastases in a prior PET-scan.
Hidden
in
Advanced Prostate Cancer
6 years ago
SPARTAN (Apalutamide)
Note that
Abiraterone
Acetate (Zytiga) is a steroidal CYP17A1 inhibitor - not a direct androgen receptor [AR] inhibitor. The confusion is probably due to the fact that hormonal therapy in all its forms ultimately targets AR.
Note that
Abiraterone
Acetate (Zytiga) is a steroidal CYP17A1 inhibitor - not a direct androgen receptor [AR] inhibitor. The confusion is probably due to the fact that hormonal therapy in all its forms ultimately targets AR.
pjoshea13
in
Advanced Prostate Cancer
7 years ago
How late is too late for Abiraterone?
This is important as there is a small (miniscule) chance that the NHS will agree later this year that
Abiraterone
should be given as standard front line treatment (it is under review by Govt).
This is important as there is a small (miniscule) chance that the NHS will agree later this year that
Abiraterone
should be given as standard front line treatment (it is under review by Govt).
Jlcwonderboy
in
Advanced Prostate Cancer
7 years ago
Interesting result for BRCA patients from ASCO2018
"Effect of germline DNA repair gene mutations on outcomes in men with metastatic castration-resistant prostate cancer receiving first-line
abiraterone
and enzalutamide."
"Effect of germline DNA repair gene mutations on outcomes in men with metastatic castration-resistant prostate cancer receiving first-line
abiraterone
and enzalutamide."
snoraste
in
Advanced Prostate Cancer
7 years ago
Quality of Life Follow up LATITUDE trial (Zytiga+Prednisone+ADT)
In LATITUDE, 1199 patients were randomized to ADT plus
abiraterone
/prednisone (597) or to ADT plus placebo (602). Median follow-up in the ADT plus
abiraterone
/prednisone group was 30.9 months; in the ADT plus placebo group, it was 29.7 months.
In LATITUDE, 1199 patients were randomized to ADT plus
abiraterone
/prednisone (597) or to ADT plus placebo (602). Median follow-up in the ADT plus
abiraterone
/prednisone group was 30.9 months; in the ADT plus placebo group, it was 29.7 months.
snoraste
in
Advanced Prostate Cancer
7 years ago
ASCO Genitourinary Cancers Symposium (Zytiga & radiation in highish-risk local PCa.)
Men received 6 months of ADT concurrently with 1000mg AA/5mg P {
abiraterone
acetate plus prednisone} daily and 78 Gy RT to prostate/SV. Primary endpoint was PSA , 0.1 ng/ml at 1 year."
Men received 6 months of ADT concurrently with 1000mg AA/5mg P {
abiraterone
acetate plus prednisone} daily and 78 Gy RT to prostate/SV. Primary endpoint was PSA , 0.1 ng/ml at 1 year."
pjoshea13
in
Advanced Prostate Cancer
7 years ago
ASCO Genitourinary Cancers Symposium (Statin use & outcomes.)
{prednisone (P),
abiraterone
(AA)} -Patrick 230 Poster Session (Board #L6), Thu, 11:30 AM-1:00 PM and 5:15 PM-6:15 PM Impact of statins on outcomes in patients (pts) with metastatic castration resistant prostate cancer (mCRPC): Post-hoc analysis of data from COU-AA-301 and COU-AA-302 trials.
{prednisone (P),
abiraterone
(AA)} -Patrick 230 Poster Session (Board #L6), Thu, 11:30 AM-1:00 PM and 5:15 PM-6:15 PM Impact of statins on outcomes in patients (pts) with metastatic castration resistant prostate cancer (mCRPC): Post-hoc analysis of data from COU-AA-301 and COU-AA-302 trials.
pjoshea13
in
Advanced Prostate Cancer
7 years ago
ASCO Genitourinary Cancers Symposium (Statins again)
"Although limited by sample size, our data showed a trend that statins may mildly enhance the anti-tumor effects of Ab {
abiraterone
}i in CRPC patients.
"Although limited by sample size, our data showed a trend that statins may mildly enhance the anti-tumor effects of Ab {
abiraterone
}i in CRPC patients.
pjoshea13
in
Advanced Prostate Cancer
7 years ago
ASCO Genitourinary Cancers Symposium (Low testosterone at first PSA failure)
Given prolonged survival when
abiraterone
or docetaxel is added to ADT in men with castrate-sensitive metastatic prostate cancer and possibly in men with localized high-risk prostate cancer provides rationale to support their use with ADT in men with low testosterone at PSA failure in the setting of
Given prolonged survival when
abiraterone
or docetaxel is added to ADT in men with castrate-sensitive metastatic prostate cancer and possibly in men with localized high-risk prostate cancer provides rationale to support their use with ADT in men with low testosterone at PSA failure in the setting of
pjoshea13
in
Advanced Prostate Cancer
7 years ago
Finally, Real Promise' for Prostate Cancers With No Therapy20+-Month Improvement in Metastasis-Free Survival
Of those whose disease progressed, 80% of patients who were given placebo and 56% of patients who were given apalutamide received open-label
abiraterone
(Zytiga, Janssen-Cilag) for metastatic castrate-resistant prostate cancer.
Of those whose disease progressed, 80% of patients who were given placebo and 56% of patients who were given apalutamide received open-label
abiraterone
(Zytiga, Janssen-Cilag) for metastatic castrate-resistant prostate cancer.
Hidden
in
Advanced Prostate Cancer
7 years ago
ASCO Genitourinary Cancers Symposium (Xofigo - Radium-223 retreatment)
No concomitant cytotoxic agents were allowed; other concomitant agents (eg,
abiraterone
, enzalutamide) were allowed at investigator discretion. The primary objective was safety.
No concomitant cytotoxic agents were allowed; other concomitant agents (eg,
abiraterone
, enzalutamide) were allowed at investigator discretion. The primary objective was safety.
pjoshea13
in
Advanced Prostate Cancer
7 years ago
ASCO Genitourinary Cancers Symposium (Olaparib and Durvalumab in metastatic castrate-resistant prostate cancer (mCRPC))
Prior treatment with enzalutamide and/or
abiraterone
is required. D is given at 1500 mg iv q28 days + O 300 mg tablets po q12 hours. The primary endpoint is PFS. Core biopsies undergo mutational analysis.
Prior treatment with enzalutamide and/or
abiraterone
is required. D is given at 1500 mg iv q28 days + O 300 mg tablets po q12 hours. The primary endpoint is PFS. Core biopsies undergo mutational analysis.
pjoshea13
in
Advanced Prostate Cancer
7 years ago
1
...
62
63
64
...
68
Next page
20
30
40
50
60
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
1268 results
Fight Prostate Cancer
53 results
Prostate Cancer Network
11 results
View top 10 communities
Sort by
Most Relevant
Newest